This paper is in the following e-collection/theme issue:

JMIR Theme Issue: COVID-19 Special Issue (2238) Drug Repurposing and Off-Label Use (19) Infodemiology and Infoveillance (1124) Medicine 2.0: Social Media, Open, Participatory, Collaborative Medicine (1399) Infectious Diseases (non-STD/STI) (1288) Infoveillance, Infodemiology, Digital Disease Surveillance, Infodemic Management (921) Mass Media/Social Media Communication and Campaigns (406) Outbreak and Pandemic Preparedness and Management (1529) Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1385)

Published on in Vol 22 , No 11 (2020) :November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/20044, first published .
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study

Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study

Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study

Authors of this article:

Kacper Niburski 1 Author Orcid Image ;   Oskar Niburski 2 Author Orcid Image
Article Authors Cited by (32) Tweetations (196) Metrics

Journals

  1. Parrish D. From the Editor—Reflecting on 2020: Science, Values, and Politics. Journal of Social Work Education 2021;57(1):1 View
  2. Mackey T, Purushothaman V, Haupt M, Nali M, Li J. Application of unsupervised machine learning to identify and characterise hydroxychloroquine misinformation on Twitter. The Lancet Digital Health 2021;3(2):e72 View
  3. Haupt M, Li J, Mackey T. Identifying and characterizing scientific authority-related misinformation discourse about hydroxychloroquine on twitter using unsupervised machine learning. Big Data & Society 2021;8(1):205395172110138 View
  4. Bojanic A. Accounting for the Trump factor in modeling the COVID-19 epidemic: the case of Louisiana. Big Data and Information Analytics 2021;6(0):74 View
  5. SUGIURA W. 5．Confronting COVID-19： Current Issues of SARS-CoV-2 Therapeutic Drug/Vaccine Development. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 2021;26(1):91 View
  6. Blankenship S, Nakano-Okuno M, Zhong R. Physicians’ Role in the COVID-19 Infodemic: A Reflection. Southern Medical Journal 2021;114(12):812 View
  7. Larsen K, Stanley E. Leaders’ Windows of Tolerance for Affect Arousal—and Their Effects on Political Decision-making During COVID-19. Frontiers in Psychology 2021;12 View
  8. Martinez Leal I, Njoh J, Chen T, Foreman-Hays F, Reed B, Haley S, Chavez K, Reitzel L, Obasi E. Exploring COVID-19 Vaccine Attitudes among Racially and Ethnically Minoritized Communities: Community Partners’ and Residents’ Perspectives. International Journal of Environmental Research and Public Health 2023;20(4):3372 View
  9. Ntompras C, Drosatos G, Kaldoudi E. A high-resolution temporal and geospatial content analysis of Twitter posts related to the COVID-19 pandemic. Journal of Computational Social Science 2022;5(1):687 View
  10. Matthews M, Matthews S, Wang D, Kelemen T. Tweet, like, subscribe! Understanding leadership through social media use. The Leadership Quarterly 2022;33(1):101580 View
  11. Rao A, Veluswamy S, Shankarappa B, Reddy R, Umesh N, John L, Mathew L, Shetty N. Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study. Expert Review of Anti-infective Therapy 2022;20(5):781 View
  12. Melissa M, Jillian J, Jennifer E, Daniel G, Andrew P. Review and thematic analysis of guiding principles for effective crisis communication using social media. Journal of Public Health and Epidemiology 2022;14(2):72 View
  13. Hua Y, Jiang H, Lin S, Yang J, Plasek J, Bates D, Zhou L. Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications. Journal of the American Medical Informatics Association 2022;29(10):1668 View
  14. Niburski K, Niburski O. Impact of Elon Musk’s Tweeting about Psychiatric Medication on the Internet, Media, and Purchasing: Observational Study. Journal of Consumer Health on the Internet 2023;27(1):12 View
  15. Trifirò G, Crisafulli S. A New Era of Pharmacovigilance: Future Challenges and Opportunities. Frontiers in Drug Safety and Regulation 2022;2 View
  16. Cracowski J, Muller S, Anglade I, Bonnefond G, Bouhanick B, Bouquet S, Cabut S, Daynès P, Denis B, Durand D, Jonville-Béra A, Lahouegue A, Léo M, Micallef J, Molimard M, Penfornis C, Querol-Ferrer V. Prevention of risks associated with inappropriate use/unnecessary consumption of medicines. Therapies 2022;77(1):79 View
  17. Bogdanić N, Močibob L, Vidović T, Soldo A, Begovać J, Karunasagar I. Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020. PLOS ONE 2022;17(2):e0263437 View
  18. Ho M, Tadrous M, Iacono A, Suda K, Gomes T. Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021. Journal of Antimicrobial Chemotherapy 2023;78(1):242 View
  19. García-Albéniz X, del Amo J, Polo R, Morales-Asencio J, Hernán M. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. European Journal of Epidemiology 2022;37(8):789 View
  20. Cracowski J, Muller S, Anglade I, Bonnefond G, Bouhanick B, Bouquet S, Cabut S, Daynès P, Denis B, Durand D, Jonville-Béra A, Lahouegue A, Léo M, Micallef J, Molimard M, Penfornis C, Querol-Ferrer V. Prévention des risques liés à un usage inapproprié/consommation inutile des médicaments. Therapies 2022;77(1):69 View
  21. Golumbic Y, Scroggie K, Kenneally C, Lin J, Blyth M, Firmer G, Rutledge P, Motion A. Meet the Medicines—A Crowdsourced Approach to Collecting and Communicating Information about Essential Medicines Online. International Journal of Environmental Research and Public Health 2023;20(5):4242 View
  22. Graham A, Pickett J, Cullen F, Jonson C, Haner M, Sloan M. Blinded by the White (Nationalism): Separatist Ideology and Discounting the Threat of COVID-19 to Society. Polity 2023;55(1):195 View
  23. Dear J. Fomepizole should not be used more liberally in paracetamol overdose. British Journal of Clinical Pharmacology 2023;89(2):599 View
  24. Prawira B, Pratama A, Bella A, Nuraini S. The role of behavioural immune system and belief in COVID-19 misinformation on COVID-19 protective behaviours in Indonesia. Journal of Health Psychology 2022;27(12):2729 View
  25. Aprilio K, Wilar G. Emergence of Ethnomedical COVID-19 Treatment: A Literature Review. Infection and Drug Resistance 2021;Volume 14:4277 View
  26. Cvek B. Multiple deadlocks in the development of nonprofit drugs. Drug Discovery Today 2022;27(9):2411 View
  27. Learoyd A, Arnold L, Reid F, Beckley-Hoelscher N, Casian A, Sangle S, Morton N, Nel L, Cape A, John S, Kim S, Shivapatham D, Luqmani R, Jayne D, Galloway J, Douiri A, D’Cruz D. The HAVEN study—hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. Trials 2023;24(1) View
  28. Thompson E. Early COVID-19 Home-Based Care Knowledge and Efficacies: Comparing Ghanaian and US Respondents. Journal of Health Communication 2023:1 View

Books/Policy Documents

  1. Bolsen T, Palm R. Molecular Biology and Clinical Medicine in the Age of Politicization. View
  2. Rahtz D, Shultz, II C, Sirgy M. Community, Economy and COVID-19. View